ArticleScientific reports2025
Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].Atencion primaria · 2026Guideline
- Fluconazole-induced liver injury in patients with pulmonary cryptococcosis: a comprehensive study integrating clinical cohort analysis, network toxicology, molecular docking, and transcriptomics.Antimicrobial agents and chemotherapy · 2026Article
- Predictive value of ALBI score and age for developing resistance to trastuzumab in HER-2-positive breast cancer patients: prediction based on a real-world case series from a single center in China.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2)-targeted therapies, including monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs), have significantly improved clinical outcomes in HER2-positive cancers. However, hepatotoxicity remains a major concern with these therapies, and a comprehensive analysis of the hepatotoxicity signals across different HER2-targeted drugs is lacking. We aim to conduct a comprehensive comparative analysis of hepatotoxicity risk related to various HER2-targeted agents. Real-world pharmacovigilance research was conducted on the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database from Q1 2012 to Q2 2024. Disproportionality analysis was used to assess the strength of hepatotoxicity signals for trastuzumab, pertuzumab, T-DM1, T-DXd, and TKIs. Reporting Odds Ratios (ROR) was calculated to identify significant hepatotoxicity signals. Moreover, the time to onset (TTO) of hepatotoxicity was also evaluated. A total of 2,986 hepatotoxicity cases concerning HER2-targeted agents were collected. The strongest hepatotoxicity signal was found with T-DM1, yielding an ROR of 6.00 (95% CI: 5.51-6.54), followed by trastuzumab with an ROR of 2.65 (95% CI: 2.52-2.79) and T-DXd with an ROR of 2.51 (95% CI: 2.25-2.80). TKIs showed an ROR of 2.36 (95% CI: 2.11-2.64), while pertuzumab demonstrated the lowest signal with an ROR of 1.73 (95% CI: 1.54-1.94). The liver toxicity of HER2-targeted drugs primarily manifests as elevated ALT, AST, and bilirubin levels. Additionally, T-DM1 can lead to hepatic coma and elevated ALP levels, while T-DXd may cause liver failure and jaundice. Besides, pertuzumab showed the shortest median TTO (21 days, interquartile range [IQR] 8-98), and trastuzumab as the longest (210 days, IQR 7-656). This study identifies significant hepatotoxicity signals associated with HER2-targeted therapies, highlights the need for regular and long-term assessment of liver enzymes and bilirubin monitoring. Despite the hepatotoxicity risks, HER2-targeted therapies remain vital in the treatment of HER2-positive cancers, requiring careful management to balance efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.